Rudolf Virchow Research Articles

Inflammatory Processes: Key Mediators of Oncogenesis and Progression in Pancreatic Ductal Adenocarcinoma (PDAC).

Associations between inflammation and cancer were first discovered approximately 160 years ago by Rudolf Virchow, who observed that tumors were infiltrated with inflammatory cells, and defined inflammation as a pathological condition. Inflammation has now emerged as one of the key mediators in oncogenesis and tumor progression, including pancreatic ductal adenocarcinoma (PDAC). However, the role of inflammatory processes in cancers is complicated and controversial, and the detailed regulatory mechanisms are still unclear. This review elucidates the dynamic interplay between inflammation and immune regulation, microenvironment alteration, metabolic reprogramming, and microbiome risk factors in PDAC, committing to exploring a deeper understanding of the role of crucial inflammatory pathways and molecules for providing insights into therapeutic strategies.

Abstract B064: Antigen-presenting type-I conventional dendritic cells facilitate curative checkpoint blockade immunotherapy in pancreatic cancer

Abstract The link between cancers and inflammation was first made by Rudolph Virchow more than a century ago when cancers were observed at sites with chronic inflammation. The host response to cancer shares many parallels with inflammation and wound healing process.Inflammation and tissue damage associated with pancreatitis can precede or occur concurrently with pancreatic ductal adenocarcinoma (PDAC). We demonstrate that in PDAC coupled with pancreatitis (ptPDAC), antigen-presenting type-I conventional dendritic cells (cDC1s) are specifically activated. Immune checkpoint blockade therapy (iCBT) leads to cytotoxic CD8+ T cell activation and eradication of ptPDAC with restoration of lifespan even upon PDAC re-challenge. Such eradication of ptPDAC was reversed following specific depletion of dendritic cells. Employing PDAC antigen-loaded cDC1s as a vaccine, immunotherapy-resistant PDAC was rendered sensitive to iCBT with a curative outcome. Analysis of the T-cell receptor (TCR) sequences in the tumor infiltrating CD8+ T cells following cDC1 vaccination coupled with iCBT identified unique CDR3 sequences with potential therapeutic significance. Our findings identify a fundamental difference in the immune microenvironment and adaptive immune response in PDAC concurrent with, or without pancreatitis, and provides a rationale for combining cDC1 vaccination with iCBT as a potential treatment option. Citation Format: Krishnan K Mahadevan, Allison M. Dyevoich, Yang Chen, Bingrui Li, Hikaru Sugimoto, Amari Sockwell, Kathleen McAndrews, Huamin Wang, Shabnam Shalapour, Stephanie Watowich, Raghu Kalluri. Antigen-presenting type-I conventional dendritic cells facilitate curative checkpoint blockade immunotherapy in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research; 2024 Sep 15-18; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl_2):Abstract nr B064.

185th anniversary of the cell theory and modern cell technologies

The article briefly reviews the history of the development of the cell theory in the 19th century and analyses the contribution of its authors Theodor Schwann, Matthias Schleiden, and Rudolf Virchow. Particular attention is paid to the development of the cell theory and its practical significance, in particular, the invention in the 20th century and further development of cell technologies. The main characteristics of cultured cells and tissues in vitro as a new experimentally created biological system are presented, and the peculiarities of the establishment of strains of cultured plant cells are discussed. Using plants as an example, the genomic variability of somatic cells is analysed both during ontogeny and in the course of their culturing in vitro. It is assumed that any somatic cell with a living (functionally active) nucleus, when isolated and subsequently cultured in vitro can restore in its offspring, including regenerated plants, the genetic polymorphism inherent in this plant species as a result of dedifferentiation and “somaclonal” variability (the latter is assumed to occur according to the N. I. Vavilov’s law of homologous series in variation). It ispostulated that a plant is a system of cell populations characterised by the plasticity of its gene pool, which is based on genome plasticity of somatic cells, which, in interaction with cellular selection, ensures the adaptability of the plant as an integral organism and creates the possibility of inheritance (transmission to offspring) of adaptive genomic changes acquired during ontogeny. It is concluded that the adaptive traits of an organism are determined by the adaptive changes in the cells, which composed it. The author also examines the main directions of modern cell technologies and their application in crop production, in medicine for the treatment and creation of new organs using stem cells, as well as in the food industry on the example of the development of technologies for the production of artificial meat using animal stem cells, etc. It is concluded that the issue of cell adaptations remains one of the most important and still insufficiently understood issues of modern biology.

Rudolf Virchow: Integrating Medicine and Social Reform for Public Health.

Rudolf Virchow, also known as Rudolf Carl Virchow, was a physician, pathologist, medical scientist, anthropologist, politician, social reformer, and role model. However, he is best known as the founder of the field of cellular pathology. He is known as "the father of modern pathology" and the founder of social medicine. He was born on October 13, 1821, in Prussia (now Swidwin, Poland) and died on September 5, 1902, in Berlin, Germany. He stressed that most diseases of mankind can be understood in terms of the dysfunction of cells. His study subjects were cell theory, disease, embolus, and thrombosis. He actively promoted social reforms and helped establish anthropology as a contemporary scientific field. He was also awarded and honored by the Copley Medal in 1892 for his notable work in "Cellular Pathology as Based Upon Physiological and Pathological Histology" and "Handbuch der Speziellen Pathologie und Therapie." Virchow said, "Medicine is a social science, and politics is nothing more than medicine on a grand scale." He believed that politics and social structures could have a significant positive or negative impact on public health, that medicine and public health practices used politically might change society, and that politicians and doctors had a moral duty to improve society.Knowing about Virchow helps us appreciate his ideas that laid the groundwork for many medical and scientific practices, the historical development of medical science, and the ongoing need to address social health factors. Virchow's contributions are still relevant in today's medical and public health fields. His work on cellular pathology forms the basis for many aspects of contemporary medicine, such as cancer, infectious diseases, and genetic disorders. His focus on social determinants of health remains a core principle in public health. Today, issues such as poverty, education, housing, and nutrition are acknowledged as factors affecting health outcomes. Virchow's beliefs in ethical responsibility, social transformation, and justice have affected medical ethics and the role of health professionals in society. This article highlights Rudolf Virchow's enormous contribution to pathology, medicine, and public health.

Virchow's Second Protocol; a 21st-Century Review.

Rudolf Virchow published several autopsy protocols in his 1876 book on postmortem examinations. The protocols demonstrate the application of the 1875 Regulations to medicolegal practice. The book went through several editions and translations throughout the remainder of the 19th century, but the second autopsy protocol was subject to scathing criticism in 1915. This article summarizes the protocol and reviews the criticism, historic context, and conclusions. Application of 21st-century practice principles is also attempted in order to test the durability of Virchow's methods and protocol across centuries.

EPEN-25. “CONCERNING EPENDYMOMAS, A FURTHER SUBDIVISION IS NEITHER MORPHOLOGICALLY NOR BIOLOGICALLY NECESSARY”: A NARRATIVE REVIEW OF RESEARCH ON EPENDYMOMAS BETWEEN 1865 AND 2024

Abstract BACKGROUND The history of research on ependymomas dates back to the nineteenth century. However, ependymomas have received much less attention than other neuro-oncological diseases. This narrative review investigates the history of ependymoma as a distinct tumour entity. METHODS A comprehensive literature search in German, English and French was carried out for publications from 1850 to 2024 in PubMed, the Internet Archive, and the library of Heidelberg University. Additionally, the evolution of the classification of ependymoma throughout the editions of the WHO classification of CNS tumours was analysed. RESULTS The first major systematic description of ependymal tumours was published in 1865 by Rudolf Virchow, who hypothesized that ependymomas originated from chronic irritations to the ependyma. In 1899, perivascular (pseudo-)rosettes were described for the first time. Subsequently, Percival Bailey and Harvey Cushing’s systematic classification efforts laid the groundwork for new advancements. Debates about the classification of ependymomas can already be found in publications by Percival Bailey or Gustave Roussy in 1924, with a major focus on the definition of ependymoblastoma as an independent entity, which was only resolved in 2016 with the introduction of the new diagnosis ETMR. Klaus Joachim Zülch’s important mid-20th-century work highlighted clinical variations within ependymomas but deemed no further stratification necessary. The WHO’s classifications in 1979, 1993, 2000 and 2007 relied on histopathology, with only minor details being adapted over the years. A new era began in 2016 with the recognition of C11orf95-RELA (ZFTA-RELA) as a defining hallmark of supratentorial ependymomas. The latest WHO classification in 2021 adopted a molecular-anatomical approach, incorporating new subgroups and abandoning histomorphological subtypes due to limited prognostic value. Tumor grading became mostly optional. CONCLUSIONS This review summarises the significant evolution in ependymoma research, particularly in the 2010s. Strikingly, many of the questions that Virchow, Bailey or Roussy investigated, remain unanswered in 2024.

Rudolph Virchow's Upper Silesia report: the starting point for his simultaneous engagement with public health and antisemitism.

In 2023 an important anniversary took place. It regards Virchow's report on the Upper Silesia epidemic typhus, which was associated with the death of numerous Polish peasants. It is also the starting point of Virchow's political career and fight against antisemitism, which has reached fearful levels in academia. Antisemitism is not new, but the recrudescence following the October 7th massacre of Jewish and not-Jewish people is appalling and recalls Virchow's vehemence of the past a few decades before the Nazi extermination of the Shoah during the World War II.

Rudolph Virchow's Public Health Engagement and Theodor Khoury's Legacy.

Rudolph Virchow's Public Health Engagement and Theodor Khoury's Legacy.

The Past and Future of Inflammation as a Target to Cancer Prevention.

Inflammation is an essential defense mechanism in which innate immune cells are coordinately activated on encounter of harmful stimuli, including pathogens, tissue injury, and toxic compounds and metabolites to neutralize and eliminate the instigator and initiate healing and regeneration. Properly terminated inflammation is vital to health, but uncontrolled runaway inflammation that becomes chronic begets a variety of inflammatory and metabolic diseases and increases cancer risk. Making damaged tissues behave as "wounds that do not heal" and sustaining the production of growth factors whose physiologic function is tissue healing, chronic inflammation accelerates cancer emergence from premalignant lesions. In 1863, Rudolf Virchow, a leading German pathologist, suggested a possible association between inflammation and tumor formation, but it took another 140 years to fully elucidate and appreciate the tumorigenic role of inflammation. Key findings outlined molecular events in the inflammatory cascade that promote cancer onset and progression and enabled a better appreciation of when and where inflammation should be inhibited. These efforts triggered ongoing research work to discover and develop inflammation-reducing chemopreventive strategies for decreasing cancer risk and incidence.

Sentient cells as basic units of tissues, organs and organismal physiology.

Cells evolved some 4 billion years ago, and since then the integrity of the structural and functional continuity of cellular life has been maintained via highly conserved and ancient processes of cell reproduction and division. The plasma membrane as well as all the cytoplasmic structures are reproduced and inherited uninterruptedly by each of the two daughter cells resulting from every cell division. Although our understanding of the evolutionary emergence of the very first cells is obscured by the extremely long timeline since that revolutionary event, the generally accepted position is that the de novo formation of cells is not possible; all present cells are products of other prior cells. This essential biological principle was first discovered by Robert Remak and then effectively coined as Omnis Cellula e Cellula (every cell of the cell) by Rudolf Virchow: all currently living cells have direct structural and functional connections to the very first cells. Based on our previous theoretical analysis, all cells are endowed with individual sentient cognition that guides their individual agency, behaviour and evolution. There is a vital consequence of this new sentient and cognitive view of cells: when cells assemble as functional tissue ecologies and organs within multicellular organisms, including plants, animals and humans, these cellular aggregates display derivative versions of aggregate tissue- and organ-specific sentience and consciousness. This innovative view of the evolution and physiology of all currently living organisms supports a singular principle: all organismal physiology is based on cellular physiology that extends from unicellular roots.

Prostatic Glandular Differentiation in Cystic Teratoma Of the Ovary in An Elderly Woman

The first documented case of teratoma dates to 1820 and was described by the French physician Geoffroy Saint-Hilaire [1]. The term "teratoma" derives from the Greek τέρας "teras", meaning "monster" or "anomaly", and -ωμα "oma", meaning "tumor" [2]. This name was coined in 1863 by German pathologist Rudolf Virchow, who studied numerous cases of tumors containing heterogeneous tissues and noted that these tumors appeared to contain "a monster" of various tissue types.

Translated article] Rudolf Virchow's Visit to Spain

Translated article] Rudolf Virchow's Visit to Spain

La visita de Virchow a España

La visita de Virchow a España

Familial Mediterranean Fever-Related Amyloidosis in Turkey: A Need for a Familial Mediterranean Fever Registry.

Amyloidosis has been well known since Rudolph Virchow named the condition in the 19th century. Most physicians were aware of the association between amyloidosis to chronic suppurative conditions and multiple myeloma. However, familial Mediterranean fever, although probably as ancient as the Galenic era, was appropriately identified only in the 21st century. The nomenclature was variable throughout history, but the name "FMF" has been universally adopted since the report from Heller and colleagues in 1958. In 1967, Sokmen and Ozdemir of Ankara University published a report on 194 patients, of whom 64 had amyloidosis. Familial Mediterranean fever constituted the cause in half of the cases. Goldfinger and Ozkan demonstrated efficacy of colchicine for treatment of familial Mediterranean fever in 1972, and further studies revealed that colchicine is also efficient for prevention of amyloidosis. However, since then, several single-center and multicenter amyloid A amyloidosis studies from Turkey have been published. Almost invariably, familial Mediterranean fever is the most common cause of systemic amyloidosis. No downward trends in percentages have been observed. Recent studies have shown that cases of amyloidosis in patients with familial Mediterranean fever are decreasing. Also, cases of amyloidosis in conjunction with suppurative conditions are on the decrease worldwide. However, according to registry data from the Turkish Society of Nephrology, the percentage of incident hemodialysis patients with amyloidosis is not decreasing. The question arises: Why is a complication that is 98% preventable still causing end-stage renal disease? We believe the lack of a stable and comprehensive registry for familial Mediterranean fever, including associated cases of amyloidosis, is the reason we cannot properly answer this question. In this work, we use a historical approach to present why a familial Mediterranean fever registry is direly needed.

Paradigm Shift in the Management of Acute Myeloid Leukemia-Approved Options in 2023.

The word Leukemia was coined nearly 200 years ago by Rudolf Virchow. Once a death sentence, Acute Myeloid Leukemia (AML) is now a treatable condition. The introduction of "7 + 3" chemotherapy, originally reported from the Roswell Park Memorial institute in Buffalo, New York, in 1973, changed the treatment paradigm for AML. About twenty-seven years later, FDA approved the first targeted agent, gemtuzumab, to be added to this backbone. During the last seven years, we have had ten new drugs approved for the management of patients with AML. Work by many dedicated scientists led to AML achieving the elite status of being the first cancer to have the whole genome sequenced using next-generation sequencing. In the year 2022, we witnessed the introduction of new classification systems for AML by the international consensus classification and the world health organization, both emphasizing molecular classification of the disease. In addition, the introduction of agents such as venetoclax and targeted therapies have changed the treatment paradigm in older patients ineligible for intensive therapy. In this review, we cover the rationale and evidence behind these regimens and provide insights into the newer agents.

Johannes Müller (1801-1858) and his school: pioneer and giant of German physiology

Johannes Müller was indisputably the most versatile and brilliant physiologist in the mid-nineteenth century. Müller was born in Koblenz in 1801 as the eldest of five children. He received an excellent education in mathematics and the ancient languages and was thus able to read with ease the writings of Aristotle in the original.He served a year with the Pioneers after graduating from high school in 1818. In 1819 he enrolled at the University of Bonn. In 1821, while still a student, he was awarded the scientific university prize for his work on foetal respiration. Müller received his doctorate at the university of Bonn in 1822. He moved to Berlin, where he continued to attend lectures by the anatomist Karl Asmund Rudolphi.He obtained his habilitation in physiology and comparative anatomy in 1824. After his years in Bonn, he accepted a chair at the University of Berlin in 1833 as Rudolphi's successor. His famous "Handbuch der Physiologie" (1833-1840) was published in Berlin. Müller's main areas of interest were physiology, human anatomy, comparative anatomy and anatomical pathology.Müller has numerous publications in addition to his famous book on physiology. He and his distinguished students (Emil du Bois-Reymond, Ernst Haeckel, Hermann von Helmholtz, Friedrich Gustav Jakob Henle, Carl Ludwig, Theodor Schwann and Rudolf Virchow amongst others) made the Berlin Physiological Institute world famous. The natural-philosophical approach to medicine that was still dominant at the beginning of the 19th century was increasingly replaced by a scientifically oriented methodology by Müller.

In-silico studies to recognize repurposing therapeutics toward arginase-I inhibitors as a potential onco-immunomodulators.

Rudolf Virchow was the first person to point out the important link between immune function and cancer. He did this by noticing that leukocytes were often found in tumors. Overexpression of arginase 1 (ARG1) and inducible nitric oxide synthase (iNOS) in myeloid-derived suppressor cells (MDSCs) and tumour-associated macrophages (TAMs) depletes both intracellular and extracellular arginine. TCR signalling is slowed as a result, and the same types of cells produce reactive oxygen and nitrogen species (ROS and RNS), which aggravates the situation. Human arginase I is a double-stranded manganese metalloenzyme that helps L-arginine break down into L-ornithine and urea. Thus, a quantitative structure-activity relationship (QSAR) analysis was performed to unearth the unrecognised structural aspects crucial for arginase-I inhibition. In this work, a balanced QSAR model with good prediction performance and clear mechanistic interpretation was developed using a dataset of 149 molecules encompassing a broad range of structural scaffolds and compositions. The model was made to meet OECD standards, and all of its validation parameters have values that are higher than the minimum requirements (R2 tr = 0.89, Q2 LMO = 0.86, and R2 ex = 0.85). The present QSAR study linked structural factors to arginase-I inhibitory action, including the proximity of lipophilic atoms to the molecule's centre of mass (within 3A), the position of the donor to the ring nitrogen (exactly 3 bonds away), and the surface area ratio. As OAT-1746 and two others are the only arginase-I inhibitors in development at the time, we have performed a QSAR-based virtual screening with 1650 FDA compounds taken from the zinc database. In this screening, 112 potential hit compounds were found to have a PIC50 value of less than 10nm against the arginase-I receptor. The created QSAR model's application domain was evaluated in relation to the most active hit molecules identified using QSAR-based virtual screening, utilising a training set of 149 compounds and a prediction set of 112 hit molecules. As shown in the Williams plot, the top hit molecule, ZINC000252286875, has a low leverage value of HAT i/i h* = 0.140, placing it towards the boundary of the usable range. Furthermore, one of 112 hit molecules with a docking score of -10.891kcal/mol (PIC50 = 10.023M) was isolated from a study of arginase-I using molecular docking. Protonated ZINC000252286875-linked arginase-1 showed 2.9 RMSD, whereas non-protonated had 1.8. RMSD plots illustrate protein stability in protonated and non-protonated ZINC000252286875-bound states. Protonated-ZINC000252286875-bound proteins contain 25 Rg. The non-protonated protein-ligand combination exhibits a 25.2-Rg, indicating compactness. Protonated and non-protonated ZINC000252286875 stabilised protein targets in binding cavities posthumously. Significant root mean square fluctuations (RMSF) were seen in the arginase-1 protein at a small number of residues for a time function of 500ns in both the protonated and unprotonated states. Protonated and non-protonated ligands interacted with proteins throughout the simulation. ZINC000252286875 bound Lys64, Asp124, Ala171, Arg222, Asp232, and Gly250. Aspartic acid residue 232 exhibited 200% ionic contact. 500-ns simulations-maintained ions. Salt bridges for ZINC000252286875 aided docking. ZINC000252286875 created six ionic bonds with Lys68, Asp117, His126, Ala171, Lys224, and Asp232 residues. Asp117, His126, and Lys224 showed 200% ionic interactions. In protonated and deprotonated states, GbindvdW, GbindLipo, and GbindCoulomb energies played crucial role. Moreover, ZINC000252286875 meets all of the ADMET standards to serve as a drug. As a result, the current analyses were successful in locating a novel and potent hit molecule that inhibits arginase-I effectively at nanomolar concentrations. The results of this investigation can be used to develop brand-new arginase I inhibitors as an alternative immune-modulating cancer therapy.

Virchow and Troy.

The Trojan war occupies an important place in Greek mythology. Homer describes this in detail in his epic works of "The Iliad" and "The Odyssey." The ancient town of Troy is located south of the Dardanelles Strait in Turkey. Until the late nineteenth century, scientists thought that the Trojan War was a legend. German businessman and amateur archaeologist Heinrich Schliemann (1822-1890) began excavations in Troy. The Turkish Empire (Ottoman Empire) granted excavation permission in 1871 on the condition that the artifacts discovered would be preserved and exhibited. Schliemann found "the treasure of the Trojan king Priam" in 1873. He smuggled the treasure to Athens. In 1874, the Ottoman government discovered this and went after the treasure. They sued Schliemann in Athens. According to archaeologists, the treasure dates back to 2600-2400 BC. The horde that Schliemann found could not have belonged to the Trojan King Priam. It was during this time that Schliemann met Rudolf Virchow (1821-1902). Virchow was interested in anthropology and prehistory. The Turkish state granted Schliemann new permission to conduct excavations. Virchow stayed in Troy for a month in 1879 as an excavation site physician. He provided health care services to the excavation workers and local people and made observations. Virchow came to Troy once again in March 1890 to attend the second Trojan conference organized by Schliemann. Virchow was also an influential politician in Berlin. He was a member of the Berlin City Council. Thanks to the relations established with Chancellor Bismarck and Kaiser Wilhelm, Virchow ensured that the Treasure of Priam would be permanently transferred to Berlin from London (it is currently at the Victoria and Albert Museum), where it was temporarily exhibited. Trojan treasures were exhibited in the Ethnological Museum (Völkerkundemuseum) and in the Martin-Gropius Bau (formerly Kunstgewerbemuseum -The Decorative Arts Museum) until 1945. After the Soviet Army entered Berlin following the Second World War, the treasure was lost. It was discovered in 1994 that the treasure was at the Pushkin Museum.

HF01-16 HISTORY OF THE SENTINEL NODE TECHNIQUE IN UROLOGICAL TUMORS, 100 YEARS SINCE ITS INCEPTION

You have accessJournal of UrologyCME1 Apr 2023HF01-16 HISTORY OF THE SENTINEL NODE TECHNIQUE IN UROLOGICAL TUMORS, 100 YEARS SINCE ITS INCEPTION Javier Perez-Ardavin, Manuel Martinez-Sarmiento, Juan José Monserrat-Monfort, Jaime Bolon, Francisco Quereda-Flores, César David Vera Donoso, and Alberto Budia Javier Perez-ArdavinJavier Perez-Ardavin More articles by this author , Manuel Martinez-SarmientoManuel Martinez-Sarmiento More articles by this author , Juan José Monserrat-MonfortJuan José Monserrat-Monfort More articles by this author , Jaime BolonJaime Bolon More articles by this author , Francisco Quereda-FloresFrancisco Quereda-Flores More articles by this author , César David Vera DonosoCésar David Vera Donoso More articles by this author , and Alberto BudiaAlberto Budia More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003243.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The lymphatic pathway and its involvement in cancer treatment has been studied for centuries. The objective of this study was to historically assess the application of of the sentinel node (SN) technique in the assessment of lymphatic spread in urologic malignancy. METHODS: We conducted a comprehensive literature review of studies evaluating lymphatic spread in urologic malignancy. Medline, Embase, Scopus, and AGORA were queried from time of database inception until 1900/2022 We evaluated temporal trends in publication by genitourinary malignancy type. RESULTS: The first reference of lymphatic dissemination was by Bartholin in 1653, with discovery of a system that conducted liquid through the body, in parallel to the blood. In 1923, Braithwaite et al. first published the concept of the "sentinel gland." In 1953, Sherman and Ter-Pogossian managed to establish the SN technique using radioisotopes. With this advance, Rudolf Virchow's hypothesis was confirmed: "the lymphatic system runs in one direction and in an orderly manner". In 1966 Sayegh et al. described for the first time the lymphatic drainage of a urological organ, such as the testicles. However, it was not until 1977, when Cabanas defined the concept of SN as we know it today in penile cancer with its clinical application. A few years later, in 1999 Wawroschek et al. developed the technique in open surgery using the injection of nanocolloids labeled with Tc99m which is still used for experimental use. Nevertheless, as we can see in the image, the trend of publications on prostate cancer is on the rise, surpassing those on penile cancer. Finally, the use of SN technique extended to kidney, muscle-invasive bladder cancer and testicle with discouraging results according to data first published in the 00´s. CONCLUSIONS: Since its inception in 1923, several authors have studied the concept of the SN in urologic malignancy, with an increase in the number of studies performed over time. While the use of SN technique is well established, its application in prostate cancer remains an experimental for trial purposes. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e261 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Javier Perez-Ardavin More articles by this author Manuel Martinez-Sarmiento More articles by this author Juan José Monserrat-Monfort More articles by this author Jaime Bolon More articles by this author Francisco Quereda-Flores More articles by this author César David Vera Donoso More articles by this author Alberto Budia More articles by this author Expand All Advertisement PDF downloadLoading ...

Why public health cannot be led by doctors only.

Why public health cannot be led by doctors only.